These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 11328944

  • 1. Whole-body L-leucine oxidation in patients with variant form of maple syrup urine disease.
    Schadewaldt P, Bodner-Leidecker A, Hammen HW, Wendel U.
    Pediatr Res; 2001 May; 49(5):627-35. PubMed ID: 11328944
    [Abstract] [Full Text] [Related]

  • 2. Assessment of whole body L-leucine oxidation by noninvasive L-[1-13C]leucine breath tests: a reappraisal in patients with maple syrup urine disease, obligate heterozygotes, and healthy subjects.
    Schadewaldt P, Bodner A, Brösicke H, Hammen HW, Wendel U.
    Pediatr Res; 1998 May; 43(5):592-600. PubMed ID: 9585004
    [Abstract] [Full Text] [Related]

  • 3. Practical methods to estimate whole body leucine oxidation in maple syrup urine disease.
    Elsas LJ, Ellerine NP, Klein PD.
    Pediatr Res; 1993 May; 33(5):445-51. PubMed ID: 8511017
    [Abstract] [Full Text] [Related]

  • 4. Effect of insulin on leucine kinetics in maple syrup urine disease.
    Collins JE, Umpleby AM, Boroujerdi MA, Leonard JV, Sonksen PH.
    Pediatr Res; 1987 Jan; 21(1):10-3. PubMed ID: 3540829
    [Abstract] [Full Text] [Related]

  • 5. Transamination and oxidative decarboxylation rates of branched-chain 2-oxo acids in cultured human skin fibroblasts.
    Schadewaldt P, Radeck W, Hammen HW, Wendel U.
    Pediatr Res; 1988 Jan; 23(1):40-4. PubMed ID: 3340442
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Oral L-alloisoleucine loading studies in healthy subjects and in patients with maple syrup urine disease.
    Schadewaldt P, Dalle-Feste C, Langenbeck U, Wendel U.
    Pediatr Res; 1991 Nov; 30(5):430-4. PubMed ID: 1754297
    [Abstract] [Full Text] [Related]

  • 9. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
    Riazi R, Rafii M, Clarke JT, Wykes LJ, Ball RO, Pencharz PB.
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thiamine response in maple syrup urine disease.
    Fernhoff PM, Lubitz D, Danner DJ, Dembure PP, Schwartz HP, Hillman R, Bier DM, Elsas LJ.
    Pediatr Res; 1985 Oct; 19(10):1011-6. PubMed ID: 3903643
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prolongation of G1 and S phase in C-6 glioma cells treated with maple syrup urine disease metabolits. Morphologic and cell cycle studies.
    Liao CL, Herman MM, Bensch KG.
    Lab Invest; 1978 Feb; 38(2):122-33. PubMed ID: 564423
    [Abstract] [Full Text] [Related]

  • 17. Protein and leucine metabolism in maple syrup urine disease.
    Thompson GN, Bresson JL, Pacy PJ, Bonnefont JP, Walter JH, Leonard JV, Saudubray JM, Halliday D.
    Am J Physiol; 1990 Apr; 258(4 Pt 1):E654-60. PubMed ID: 2185648
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Glucose and alanine metabolism in children with maple syrup urine disease.
    Haymond MW, Ben-Galim E, Strobel KE.
    J Clin Invest; 1978 Aug; 62(2):398-405. PubMed ID: 670400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.